array:23 ["pii" => "S2254887420300813" "issn" => "22548874" "doi" => "10.1016/j.rceng.2020.07.002" "estado" => "S300" "fechaPublicacion" => "2020-10-01" "aid" => "1832" "copyright" => "Elsevier España, S.L.U. and Sociedad Española de Medicina Interna (SEMI)" "copyrightAnyo" => "2020" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "cor" "cita" => "Rev Clin Esp. 2020;220:461-2" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "Traduccion" => array:1 [ "es" => array:19 [ "pii" => "S0014256520301107" "issn" => "00142565" "doi" => "10.1016/j.rce.2020.04.004" "estado" => "S300" "fechaPublicacion" => "2020-10-01" "aid" => "1832" "copyright" => "Elsevier España, S.L.U. and Sociedad Española de Medicina Interna (SEMI)" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "cor" "cita" => "Rev Clin Esp. 2020;220:461-2" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "es" => array:10 [ "idiomaDefecto" => true "cabecera" => "Correspondencia" "titulo" => "Tomar o no tomar «decisiones en caliente» respecto al tratamiento de la infección por SARS-CoV-2" "tienePdf" => "es" "tieneTextoCompleto" => "es" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "461" "paginaFinal" => "462" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Whether to make decisions «on the fly» regarding treatment for SARS-CoV-2 infection" ] ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "V. Abril López de Medrano, E. Merino de Lucas, M. Salavert Lletí" "autores" => array:3 [ 0 => array:2 [ "nombre" => "V." "apellidos" => "Abril López de Medrano" ] 1 => array:2 [ "nombre" => "E." "apellidos" => "Merino de Lucas" ] 2 => array:2 [ "nombre" => "M." "apellidos" => "Salavert Lletí" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S2254887420300813" "doi" => "10.1016/j.rceng.2020.07.002" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2254887420300813?idApp=WRCEE" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0014256520301107?idApp=WRCEE" "url" => "/00142565/0000022000000007/v1_202009260731/S0014256520301107/v1_202009260731/es/main.assets" ] ] "itemAnterior" => array:19 [ "pii" => "S2254887420300746" "issn" => "22548874" "doi" => "10.1016/j.rceng.2020.05.007" "estado" => "S300" "fechaPublicacion" => "2020-10-01" "aid" => "1861" "copyright" => "Elsevier España, S.L.U. and Sociedad Española de Medicina Interna (SEMI)" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "cor" "cita" => "Rev Clin Esp. 2020;220:459-61" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "en" => array:10 [ "idiomaDefecto" => true "cabecera" => "Correspondence" "titulo" => "Pulmonary embolism and COVID-19: A paradigm change" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "459" "paginaFinal" => "461" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Tromboembolismo pulmonar y COVID-19: un cambio de paradigma" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "A. Franco-Moreno, N. Muñoz-Rivas, B. Mestre-Gómez, J. Torres-Macho" "autores" => array:4 [ 0 => array:2 [ "nombre" => "A." "apellidos" => "Franco-Moreno" ] 1 => array:2 [ "nombre" => "N." "apellidos" => "Muñoz-Rivas" ] 2 => array:2 [ "nombre" => "B." "apellidos" => "Mestre-Gómez" ] 3 => array:2 [ "nombre" => "J." "apellidos" => "Torres-Macho" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S0014256520301405" "doi" => "10.1016/j.rce.2020.05.006" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0014256520301405?idApp=WRCEE" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2254887420300746?idApp=WRCEE" "url" => "/22548874/0000022000000007/v2_202010040643/S2254887420300746/v2_202010040643/en/main.assets" ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "Correspondence" "titulo" => "Whether to make decisions "on the fly" regarding treatment for SARS-CoV-2 infection" "tieneTextoCompleto" => true "saludo" => "Dear Director," "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "461" "paginaFinal" => "462" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "V. Abril López de Medrano, E. Merino de Lucas, M. Salavert Lletí" "autores" => array:3 [ 0 => array:4 [ "nombre" => "V." "apellidos" => "Abril López de Medrano" "email" => array:1 [ 0 => "vicente.abril.lopezdemedrano@gmail.com" ] "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "*" "identificador" => "cor0005" ] ] ] 1 => array:3 [ "nombre" => "E." "apellidos" => "Merino de Lucas" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "b" "identificador" => "aff0010" ] ] ] 2 => array:3 [ "nombre" => "M." "apellidos" => "Salavert Lletí" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "c" "identificador" => "aff0015" ] ] ] ] "afiliaciones" => array:3 [ 0 => array:3 [ "entidad" => "Consorcio Hospital General Universitario de Valencia, Valencia, Spain" "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:3 [ "entidad" => "Hospital General Universitario de Alicante, Alicante, Spain" "etiqueta" => "b" "identificador" => "aff0010" ] 2 => array:3 [ "entidad" => "Hospital Universitario y Politécnico La Fe, Valencia, Spain" "etiqueta" => "c" "identificador" => "aff0015" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Tomar o no tomar «decisiones en caliente» respecto al tratamiento de la infección por SARS-CoV-2" ] ] "textoCompleto" => "The outbreak of the COVID-19 pandemic is a challenge of enormous dimensions for healthcare professionals, public health, and politicians.As of April 5, 2020, official figures revealed that there were 135,032 people infected, 13,055 deaths, and 59,662 patients hospitalized (<a href="https://covid19.isciii.es/">https://covid19.isciii.es/</a>). We lived through convulsive days in which treatment protocols for COVID-19 infection were modified practically daily based on new evidence and the need to optimize the scarce therapeutic arsenal available.Just three weeks ago, we learned the results of a clinical trial that compared lopinavir/ritonavir to supportive treatment in severe patients hospitalized with COVID-19 infection whose primary outcome was time until clinical improvement.<a class="elsevierStyleCrossRef" href="#bib0005">1</a> The poor overall results in terms of clinical response and mortality led, in just a few hours, to a rare wave of pessimism among the groups of professionals in charge of making decisions in many hospitals. This was reflected in heated discussions via WhatsApp and other forums, leading to the abrupt removal of lopinavir/ritonavir from the treatment protocols of several large centers in our country.Nevertheless, the result of the information from a trial such as that one must be taken cautiously and analyzed with a critical, rigorous eye. The work suffers from various methodological problems in the design and in patient recruitment related to the urgent nature of the work. The authors themselves recognize these aspects in the discussion. Patient assignment was not blind and the desirable placebo control was not able to be established for patients who did not receive the drug in said study. Likewise, plasma levels of lopinavir/ritonavir were not able to be determined and could have been compromised in critical patients.On the other hand, the study lacks power for outcomes that are secondary in the design, but which are important, such as mortality. Assuming the same premises as for the principal variable, between 200 and 860 additional patients would have been needed in each arm to demonstrate differences. In addition, although the overall benefit was weak, a close reading allows for observing how the use of lopinavir/ritonavir could point towards a trend in mortality reduction if it is used in the first 12 days. Among patients treated earlier, the primary objective was indeed achieved, with respective mortality of 15% versus 27% in each arm. What’s more, the other secondary aims, such as a stay in the intensive care unit (5 days of difference) and the percentage of patients who developed ARDS (12% versus 24%), were also improved.In our opinion, the fundamental issue is that patients were treated too late (median of 13 days from onset of symptoms) and in monotherapy. Therefore, although it did not achieve the primary aim, the results indicate that the treated group could progress better. Therefore, it remains to be determined if the use of lopinavir/ritonavir in the earliest phases and/or in combination with other potentially active drugs would benefit patients or not.Nevertheless, we are aware of the lack of trust that protease inhibitors and their limited in vitro activity generate and in their clinical efficacy in this novel coronavirus and in others (SARS-CoV, MERS-CoV).<a class="elsevierStyleCrossRefs" href="#bib0010">2,3</a> The controversial results of this study had already in part been anticipated in another Chinese study,<a class="elsevierStyleCrossRef" href="#bib0020">4</a> which did not demonstrate a benefit to treatment with lopinavir/ritonavir and abidol. Furthermore, Janssen has reported unpublished data on the inefficacy of darunavir/cobicistat in the treatment of 30 patients with COVID-19.<a class="elsevierStyleCrossRef" href="#bib0025">5</a>Even so, while awaiting new evidence or consolidated alternative therapies, it seems prudent to continue using the optimize form of the few drugs we do have available.In catastrophic times, it is important to keep a cool head and even keel when it comes to making decisions that may determine a patient’s prognosis." "pdfFichero" => "main.pdf" "tienePdf" => true "NotaPie" => array:1 [ 0 => array:2 [ "etiqueta" => "☆" "nota" => "Please cite this article as: Abril López de Medrano V, Merino de Lucas E, Salavert Lletí M. Tomar o no tomar «decisiones en caliente» respecto al tratamiento de la infección por SARS-CoV-2. Rev Clin Esp. 2020;220:461–462." ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0005" "bibliografiaReferencia" => array:5 [ 0 => array:3 [ "identificador" => "bib0005" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Trial of lopinavir-ritonavir in adults hospitalized with severe covid-19" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "B. Cao" 1 => "Y. Wang" 2 => "D. Wen" 3 => "W. Liu" 4 => "J. Wang" 5 => "G. Fan" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMoa2001282" "Revista" => array:3 [ "tituloSerie" => "N Engl J Med" "fecha" => "2020" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32222134" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0010" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "V.C.C. Cheng" 1 => "S.K.P. Lau" 2 => "P.C.Y. Woo" 3 => "K.Y. Yuen" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Clin Microbiol Rev" "fecha" => "2007" "volumen" => "20" "paginaInicial" => "660" "paginaFinal" => "694" ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0015" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "From SARS to MERS, thrusting coronaviruses into the spotlight" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "Z. Song" 1 => "Y. Xu" 2 => "L. Bao" 3 => "L. Zhang" 4 => "P. Yu" 5 => "Y. Qu" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.3390/v11010059" "Revista" => array:6 [ "tituloSerie" => "Viruses" "fecha" => "2019" "volumen" => "11" "paginaInicial" => "E59" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/30646565" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S1878875018313068" "estado" => "S300" "issn" => "18788750" ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0020" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Efficacies of lopinavir/ritonavir and abidol in the treatment of novel coronavirus pneumonia" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "C. Jun" 1 => "L. Yun" 2 => "X. Xiuhong" 3 => "L. Ping" 4 => "L. Feng" 5 => "L. Tao" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.3760/cma.j.cn311365-20200210-00050" "Revista" => array:3 [ "tituloSerie" => "Chin J Infect Dis" "fecha" => "2020" "volumen" => "38" ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0025" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Results from a single center, open label, randomized, and controlled trial conducted at Shanghai Public Health Clinical Center (SPHCC) of darunavir and cobicistat (DRV/c) in treating laboratory-confirmed 30 COVID-19 patients showed that DRV/c was not effective. Available in: <a target="_blank" href="https://www.jnj.com/lack-of-evidence-to-support-darunavir-based-hiv-treatments-for-coronavirus">https://www.jnj.com/lack-of-evidence-to-support-darunavir-based-hiv-treatments-for-coronavirus</a>. [Accessed 6 April 2020]." ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/22548874/0000022000000007/v2_202010040643/S2254887420300813/v2_202010040643/en/main.assets" "Apartado" => array:4 [ "identificador" => "71813" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Correspondence" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/22548874/0000022000000007/v2_202010040643/S2254887420300813/v2_202010040643/en/main.pdf?idApp=WRCEE&text.app=https://revclinesp.es/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2254887420300813?idApp=WRCEE"]

Revista Clínica Española (English Edition)

ISSN: 2254-8874

Revista Clínica Española published its first issue in 1940 and is the body of expression of the Spanish Society of Internal Medicine (SEMI).
The journal fully endorses the goals of updating knowledge and facilitating the acquisition of key developments in internal medicine applied to clinical practice. Revista Clínica Española is subject to a thorough double blind review of the received articles written in Spanish or English. Ten issues are published each year, including mostly originals, reviews and consensus documents.

Indexed in:

Current Contents / Clinical Medicine , JCR / SCI-Expanded, Index Medicus / Medline y Excerpta Medica / EMBASE

Subscribe:

Impact factor

The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years.

© Clarivate Analytics, Journal Citation Reports 2022

Impact factor 2023

2.3

Citescore

CiteScore measures average citations received per document published.

Citescore 2023

0.7

SJR

SRJ is a prestige metric based on the idea that not all citations are the same. SJR uses a similar algorithm as the Google page rank; it provides a quantitative and qualitative measure of the journal's impact.

SJR 2023

0.162

SNIP

SNIP measures contextual citation impact by wighting citations based on the total number of citations in a subject field.

SNIP 2023

0.211

View more metrics

Open Access Option

Journal Information

Previous article | Next article

Lee este artículo en Español

Export reference

Download PDF

Purchase article

For the purchase of this article it is necessary to fill in the following form:

Name *

First surname *

Second surname

Email *

Address *

Number *

City *

Afganistan

Albania

Alemania

Andorra

Angola

Anguilla

Antartica

Antigua and barbuda

Antillas holandesas

Arabia saudita

Argelia

Argentina

Armenia

Aruba

Australia

Austria

Azerbaijan

Bahamas

Bahrain

Bangladesh

Barbados

Belarus

Belgica

Belice

Benin

Bermudas/antillas britanicas

Bhutan

Bolivia

Bosnia y herzegowina

Botswana

Brasil

Brunei darussalam

Bulgaria

Burkina faso

Burundi

Cabo verde

Camboya

Camerun

Canada

Chad

Chile

China

Chipre

Colombia

Comoros

Corea

Costa rica

Cote d´ivoire

Croacia

Cuba

Dinamarca

Djibouti

Dominica

East timor

Ecuador

Egipto

El salvador

Emiratos arabes unidos

Eritrea

Escocia

Eslovaquia

Eslovenia

España

Estados federados de micronesia

Estados unidos

Estonia

Etiopia

Fiji

Filipinas

Finlandia

Francia

Gabon

Gambia

Georgia

Ghana

Gibraltar

Grecia

Grenada

Groenlandia

Guadalupe

Guam

Guatemala

Guayana britanica

Guinea

Guinea ecuatorial

Guinea francesa

Guinea-bissau

Haiti

Holanda

Honduras

Hong kong

Hungria

India

Indonesia

Irak

Iran

Irlanda

Isla bouvet

Isla cocos (keeling)

Isla cook

Isla mauricio

Isla navidad

Isla norfolk

Islandia

Islas caiman

Islas falkland (malvinas)

Islas faroe

Islas georgia del sur y sandwich

Islas heard and mc donald

Islas marshall

Islas northern mariana

Islas salomon

Islas svalbard and jan mayen

Islas turks and caicos

Islas united states minor outlyi

Islas virgenes (britanicas)

Islas virgenes (u.s.a.)

Islas wallis and futuna

Israel

Italia

Jamaica

Japon

Jordania

Kazakhstan

Kenia

Kiribati

Kuwait

Kyrgyzstan

Lesoto

Letonia

Libano

Liberia

Libia arab jamahiriya

Liechtenstein

Lituania

Luxemburgo

Macao

Macedonia

Madagascar

Malasia

Malawi

Maldives

Mali

Malta

Marruecos

Martinica

Mauritania

Mayotte

Mexico

Monaco

Mongolia

Monserrat

Morocco

Mozambique

Myanmar

Namibia

Nauru

Nepal

Nicaragua

Niger

Nigeria

Niue

Noruega

Nueva caledonia

Nueva zelanda

Oman

Pakistan

Palau

Panama

Papua new guinea

Paraguay

Peru

Pitcairn

Polinesia francesa

Polonia

Portugal

Posesiones gran bretaña

Posesiones u.s.a.

Puerto rico

Qatar

Reino unido

Republica checa

Republica de africa central

Republica de cabo verde

Republica de congo

Republica de corea

Republica de moldova

Republica democratica de laos

Republica democratica del congo

Republica dominicana

Reunion

Ruanda

Rumania

Rusia

Sahara occidental

Saint kitts and nevis

Samoa

Samoa americana

San marino

San tomas y principe

San vincent and the grenadines

Santa lucia

Senegal

Serbia

Seychelles

Sierra leona

Singapur

Siria

Somalia

Sri lanka

St. helena

St. pierre and miquelon

Sudafrica

Sudan

Suecia

Suiza

Surinam

Swaziland

Tailandia

Taiwan republica de china

Tajikistan

Tanzania

Territorio de indias britanicas

Togo

Tokelau

Tonga

Trinidad and tobago

Tunisia

Turkmenistan

Turquia

Tuvalu

Ucrania

Uganda

Uruguay

Uzbekistan

Vanuatu

Vaticano

Venezuela

Vietnam

Yemen

Yugoslavia

Zambia

Zimbawe

Lebanon

Paises bajos

A coruña

Alava

Albacete

Alicante

Almeria

Asturias

Avila

Badajoz

Balears

Barcelona

Bizkaia

Burgos

Caceres

Cadiz

Cantabria

Castellon

Ceuta

Ciudad real

Cordoba

Cuenca

Girona

Granada

Guadalajara

Guipuzcoa

Huelva

Huesca

Jaen

La rioja

Las palmas

Leon

Lleida

Lugo

Madrid

Malaga

Melilla

Murcia

Navarra

Ourense

Palencia

Pontevedra

Salamanca

Segovia

Sevilla

Soria

Tarragona

Tenerife

Teruel

Toledo

Valencia

Valladolid

Zamora

Zaragoza

-- Not applicable --

Código postal *

Phone *

NIF o número identificativo *

I accept to receive information about Elsevier's special products and promotions by email

I accept to receive information about products and special promotions from Elsevier partners by email

I have read and understand the Privacy Policy and Terms and conditions and agree to be bound by all of its terms.

* Required fields

In addition to temporary access to the article, it will be sent by email.

Customer Support

Phone

Calls from Spain

932 415 960

Calls from abroad

+34 932 415 960

Hours from 9 a.m. to 6 p.m. except the months of July and August, which will be from 9 am to 3 pm.

Highlighted articles

Recommendations of the Spanish-Portuguese Internal Medicine services in the fight against climate change and environmental degradation

Publish in

Revista Clínica Española

Free access articles

The value of multi-modal ultrasound in the assessment of...

Rev Clin Esp. 2024;224:437-44

Adverse cardiovascular, obstetric and perinatal events...

Rev Clin Esp. 2024;224:337-45

How to detect non-institutionalized older patients at risk...

Rev Clin Esp. 2024;224:217-24

Revista Clínica Española (English Edition) is a member and subscribes the principles of, the Committee on Publication Ethics (COPE)
www.publicationethics.org.

Indexed in:

Follow us:

Subscribe:

Purchase article

Subscribe to our newsletter